Volume 190 - Issue 6
Hepatosplenic T-cell lymphoma following infliximab therapy for Crohn’s disease
Authors: Daniel C Burger and Timothy H J Florin
Med J Aust 2009; 190 (6): 341-342. || doi: 10.5694/j.1326-5377.2009.tb02435.x
Published online: 16 March 2009
Published online: 16 March 2009
To the Editor: We read with great interest Drini and colleagues’ recent report of hepatosplenic T-cell lymphoma (HSTCL) associated with inflammatory bowel disease. The occurrence of this rare lymphoma is partly driving a move away from the use of combination thiopurine and anti-tumour necrosis factor alpha therapy. It is important to recognise that risk of HSTCL is not only associated with exposure to thiopurine drugs with or without infliximab. It is associated with immunocompromise in general, and also occurs de novo. Explaining relative risks to patients is never easy and needs to be balanced with the need for treatment in properly selected patients.
Contrary to a comment by Drini and colleagues, HSTCL has been reported in association with exposure to adalimumab, another anti-tumour necrosis factor alpha agent.2 Two of these cases occurred in patients with prior exposure to thiopurines and infliximab, and the third occurred in a patient with rheumatoid arthritis who was not exposed to thiopurine or infliximab. There has been a recent spate of reports of HSTCL in patients with inflammatory bowel disease treated with immunomodulator therapy, but most HSTCL appears to occur in patients without exposure to immunosuppressants.3 Also, although cases predominantly occur in young men (under 22 years), HSTCL is not limited to the paediatric age group.3,4 The presentation also occurs in females, including during pregnancy.
More generally, in patients with inflammatory bowel disease, treatment with thiopurines appears to increase the risk of lymphoma two- to fourfold.5 Assuming a fourfold increase in risk, this translates into one additional lymphoma per year for every 4357 patients treated with thiopurines at age 20–29 years.5 This should be compared with the lifetime attributable risk of death from any cancer due to a single abdominal computed tomography scan performed at the age of 20, which is in the order of 1 : 2000.6 Currently, it is difficult to completely disentangle the many different factors — including patient age; severity, duration and course of disease;7 type of immunosuppression; and exposure to radiation — when considering the risk of lymphoma in inflammatory bowel disease. However, in many patients with severe disease, this risk appears to be outweighed by the benefits of adequate medical control.
Competing interests
We both received travel assistance from Abbott and Schering-Plough to attend Digestive Disease Week 2008.
References
- Drini M, Prichard PJ, Brown GJE, Macrae FA. Hepatosplenic T-cell lymphoma following infliximab therapy for Crohn’s disease. Med J Aust 2008; 189: 464-465. <eMJA full text>
- Shale M, Kanfer E, Panaccione R, Ghosh S. Hepatosplenic T-cell lymphoma in inflammatory bowel disease. Gut 2008; 57: 1639-1641. 0_i1091857
- Belhadj K, Reyes F, Farcet J-P, et al. Hepatosplenic T-cell lymphoma is a rare clinicopathologic entity with poor outcome: report on a series of 21 patients. Blood 2003; 102: 4261-4269. 0_i1091859
- Niitsu N, Kohri M, Togano T, et al. Development of hepatosplenic gammadelta T-cell lymphoma with pancytopenia during early pregnancy: a case report and review of the literature. Eur J Haematol 2004; 73: 367-371. 0_i1091861
- Kandiel A, Fraser AG, Korelitz BI, et al. Increased risk of lymphoma among inflammatory bowel disease patients treated with azathiopurine and 6-mercaptopurine. Gut 2005; 54: 1121-1125. 0_i1091863
- Brenner DJ, Hall EJ. Computed tomography — an increasing source of radiation exposure. N Engl J Med 2007; 357: 2277-2284. 0_i1091865
- Grulich AE, Vajdic CM, Cozen W. Altered immunity as a risk factor for non-Hodgkin lymphoma. Cancer Epidemiol Biomarkers Prev 2007; 16: 405-408. 0_CBBFDEEF
Early-Onset Colorectal Cancer With Liver-Only Metastases: A Retrospective Cohort Study Integrating Prospectively Collected Real-World Clinical and Molecular Data From an Australian National Database (2009–2024) to Guide Treatment Planning
Savio G. Barreto, Christos S. Karapetis, Shahid Ullah, Matthew Burge, Susan Caird, Angus Campbell, Azim Jalali, Ross Jennens, Muhammad A. Khattak, Belinda Lee, Stephanie H. Lim, Shehara Mendis, Louise Nott, Timothy J. Price, Jeremy D. Shapiro, Jeanne Tie, Javier Torres, Colin Williams, Rachel Wong, Vanessa Wong, Peter Gibbs
Australian Pathways for Specialist Pain Management and Early Palliative Care for People With Pancreatic Cancer: Developed Using a Community Consensus Approach
Jennifer Philip, Melanie R. Lovell, Kylee Bellingham, Gail Garvey, Gregory B. Crawford, Nicole M. Rankin, Kara Burns, Isabel Young, Vivienne Milch, Dorothy Keefe, Katrina Anderson, James Lawson, Meinir Krishnasamy
Cause‐specific mortality among Queensland people with cirrhosis, by cirrhosis aetiology and decompensation status, 2007–22: a retrospective cohort study
Vikas Bhasker, Jessica R Fong, Paul J Clark, Gunter F Hartel, Richard Skoien, James O’Beirne, Elizabeth E Powell, Patricia C Valery
Clinical practice guidelines for hepatocellular carcinoma surveillance for people at high risk in Australia: summary of recommendations
Jacob George, Nicole L Allard, Stuart K Roberts, Leon A Adams, Jane Davies, Behzad Hajarizadeh, Jennifer H MacLachlan, Suzanne E Mahady, Rosalie Altus, Catherine Brown, David C Fry, Belinda Greenwood‐Smith, Natali Smud, Patricia C Valery, Nafisa Yussf, Kate Broun, Denise Campbell, Karen Canfell, Chelsea Carle Harrison, Victoria Freeman, Paul Grogan, Catherine Holliday, Suzanne Hughes, Anna Kelly, Cathelijne Kemenade, Claire Latumahina, Amanda McAtamney, Megan Varlow, Joachim Worthington, Susan Yuill, Eleonora Feletto
Assessment of metabolic dysfunction‐associated fatty liver disease in primary care: a consensus statement summary
Leon A Adams, William W Kemp, Kate R Muller, Elizabeth E Powell, Stuart K Roberts, Luis Calzadilla Bertot, Stephanie Best, Gary Deed, Jon D Emery, Samantha L Hocking, Graham R Jones, John S Lubel, Sinead Sheils, Stephen M Twigg, Gerald F Watts, Jacob George
Treatment outcomes for people with hepatitis C referred to tertiary care in Victoria, 2021–22: a retrospective observational study
Elly Layton, Nicole Matthews, Brendan Quinn, Nasra Higgins, Gabrielle Lindeman, Mielle Abbott, Jennifer MacLachlan, Elizabeth Birbilis, Margaret E Hellard, Joseph Doyle, Benjamin C Cowie, Mark Stoové